DYRK1A and diabetes mellitus: Small-molecule pharmacological inhibitors of DYRK1A, such as harmine, are actively being developed for the treatment of diabetes, because they promote expansion of insulin-secreting pancreatic ®-cells [47] and appear well-tolerated in both animal models and human volunteers [47–49].